The global market for exophthalmos treatment is on a growth trajectory, with its valuation climbing from USD 251.2 million in fiscal year 2022 to USD 271.8 million in fiscal year 2023. Industry projections suggest sustained growth, culminating in a market value of USD 598 million by 2033, fueled by increasing prevalence and advancements in therapeutic interventions.
Graves’ disease remains the leading cause of exophthalmos, a condition that manifests with ocular involvement in 25β50% of cases. Intriguingly, ocular dysfunction associated with thyroid problems can manifest up to 20 years after or 10 years before a thyroid condition diagnosis, highlighting the complexity and long-term impact of the disease. Between 2023 and 2033, this interplay of disorders is expected to drive significant demand for effective exophthalmos therapies.
A pivotal study by Biomed Central Ltd., published in September 2020, underscores the growing burden of exophthalmos-related illnesses. The research reveals that 86.2% of exophthalmos patients globally are linked to hyperthyroidism, with 10.36% linked to hypothyroidism and 7.9% to euthyroidism. This rising prevalence highlights the urgency for effective treatments, creating a robust foundation for market growth in the years to come.
North America: A Promising Market for Exophthalmos Treatment
The North American region is projected to lead the global exophthalmos treatment market, driven by a significant patient base and ongoing innovations in treatment methodologies. According to the American Academy of Ophthalmology, approximately 18 in 100,000 Americans are affected by exophthalmos, signaling a considerable market opportunity.
Recent advancements in drug development and treatment modalities have further catalyzed market growth in the region. These breakthroughs are expected to unlock new opportunities for regional manufacturers, setting the stage for sustained growth during the forecast period.
With an expanding patient pool and continuous innovation, the global exophthalmos treatment market is positioned for dynamic expansion. Stakeholders across the healthcare spectrum can look forward to significant opportunities as the demand for effective therapies continues to rise.
Key Takeaways from the Market Study:
- The market for exophthalmos treatment expanded at a CAGR of 6.4% during the historical period of 2018 to 2022.
- The market for exophthalmos treatment is expected to grow steadily from 2023 to 2033, at a 8.2% CAGR.
- It is projected that the non-surgical segment by treatment type will dominate in 2023 with a 53% revenue share.
- With a 25% market share in 2023, the specialty clinic sector by end-user will hold the second-largest segment throughout the projected period.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 8.7%.
- From 2023 to 2033, the Asia Pacific exophthalmos treatment market is anticipated to expand at a stable CAGR of 7.1%.
βThe increasing incidences of hyperthyroidism along with Gravesβ disease have been accelerating the growth of the global exophthalmos market during the forecast period.β comments a Future Market Insights analyst.
Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!
Competitive Landscape:
- Eyevance Pharmaceuticals
- Sling Therapeutics
- Competition Deep Dive
- AbbVie
- Alcon
- Avik Pharma
- Anuh Pharma Ltd.
- Pfizer CentreOne
- Pipelinepharma
- Mylan N.V.
- Manus Aktteva Biopharma LLP
- Roche
Some of the recent developments in this domain are:
- EyeBiotech Ltd., a privately owned ophthalmology biotechnology business seeking to develop a new generation of eye disease therapeutics, announced the successful conclusion of a $65 million Series A fundraising round in 2022. Samsara BioCapital, Jeito Capital, and SV Health Investors spearheaded the round, with additional funding provided by MRL Ventures. A multinational team of executives as well as investors with a long history of creating ground-breaking ophthalmology medicines are brought together for the Series A.
Key Segments Covered In The Exophthalmos Treatment Market Report
Exophthalmos Treatment Market By Treatment:
- Non-surgical Treatment
- Sympathomimetic Amines
- Corticosteroids
- Secondary Metabolites
- Monoclonal Antibodies
- Radiotherapy
- Surgical Treatment
- Orbital Decompression
- Eye Muscle Surgery
- Eyelid Surgery
Exophthalmos Treatment Market By End User:
- Hospital Pharmacies
- Specialty Clinics
- Others
Exophthalmos Treatment Market By Region:
- North America
- Latin America
- Asia Pacific
- Europe
- Middle East & Africa (MEA)
ππ±π©π₯π¨π«π π ππβπ¬ πππ₯ππππ ππ§π π¨π’π§π ππ¨π―ππ«ππ π π¨π§ ππππ₯ππ‘πππ«π πππ«π€ππ ππ§π¬π’π π‘ππ¬ ππ¨π¦ππ’π§:
Short-Acting Beta-Agonists Industry
Bronchiectasis Therapeutic Industry
Blood Volume Analyzer Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:Β Β Β Β Β Β Β Β
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries:Β sales@futuremarketinsights.com
Website:Β https://www.futuremarketinsights.com
LinkedIn|Β Twitter|Β Blogs | YouTube